Physician profile
Daniel C Dapprich
NPI 1578549242
$1,294.65
in general payments reported to CMS, 2019-2025
15 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.68 · 2020: $12.36 · 2021: $15.19 · 2022: $338 · 2023: $306 · 2024: $282 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $855.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $392.86 | 2019-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $275.22 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $139.48 | 2023-2024 | Sotyktu |
| Pfizer INC. | $81.57 | 2020-2023 | |
| Janssen Biotech, INC. | $76.02 | 2022 | |
| Kyowa Kirin, INC. | $68.87 | 2022-2025 | Poteligeo |
| Celgene Corporation | $44.80 | 2019 | |
| Leo Pharma INC. | $39.87 | 2025 | Adbry |
| Organon LLC | $39.45 | 2024 | |
| Genentech USA, INC. | $30.53 | 2022 | |
| Amgen INC. | $29.44 | 2025 | Otezla |
| Arcutis Biotherapeutics, INC. | $23.59 | 2024 | Zoryve |
| Ucb, INC. | $22.04 | 2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $15.72 | 2023 | Dupixent |
| Incyte Corporation | $15.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dapprich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.